A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity
Latest Information Update: 17 Aug 2022
At a glance
- Drugs Biropepimut-S (Primary) ; Cyclophosphamide; Poly ICLC; Sargramostim
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Gliknik
- 13 Aug 2022 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 16 Dec 2021 This trial has been discontinued in Poland, according to European Clinical Trials Database record.